Hello Flowers I'm interested in how people use CD11b. What antibodies do you set it up with, and what information do you expect to get? We use it in the combination CD7/CD11b/HLA-Dr. We include CD7 to distinguish T cell malignancies(7+11b-) from myeloid . Early myeloid cells are also positive with BD CD7 FITC, so the CD7/CD11b shows a characteristic maturation curve in normal bone marrow and malignant populations distort this curve. We included HLA-Dr after Mike Loken demonstrated its usefullnes against CD11b at last year's AFCG methods course. Our soulsearching has arisen because we recently participated in a QAP programme in which there was an M4 AML. Half of the participants reported the cells as being CD7+ (we found them to be 7+11b+) and half reported them as negative. So I guess I'd like your thoughts and experience on 1)CD7 positivity in myeloid cells - do antibodies other than BD give a different result? and 2)what combinations of antibodies do you use with CD11b, and what information do you expect to get from them? Beth Rees Royal Hobart Hospital Hobart Tasmania
This archive was generated by hypermail 2b29 : Wed Apr 03 2002 - 11:53:25 EST